Diagit

Quick links to important sections

Diagit

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diagit

Property Description
Active ingredients Attapulgite, Pectin
Form Tablet, Liquid suspension
Pharmacological class Antidiarrheal; Intestinal Adsorbent
Common use Symptomatic relief of acute intestinal upset
Origin Natural-derived (Clay mineral, Polysaccharide)

Diagit is a combination drug specifically classified as an antidiarrheal agent, belonging to the functional group of intestinal adsorbents. This medication is formulated for oral administration and acts locally within the gastrointestinal tract to provide physical relief from symptoms of acute intestinal upset.

The classification as an intestinal adsorbent signifies that the drug's therapeutic benefit is achieved through a non-systemic mechanism, where the components physically bind to substances inside the intestine instead of being significantly absorbed into the bloodstream. Attapulgite, specifically, possesses a high binding capacity. This physical action helps reduce the fluid and substances that contribute to loose stools.

Composition: Attapulgite, Pectin, and Origin

The core constituents of Diagit are the two active ingredients, Attapulgite and Pectin, both of which are natural-derived substances. Attapulgite is a highly porous clay mineral, while Pectin is a plant-derived polysaccharide often sourced from fruit rinds. This preparation is typically available in common dosage forms such as a chewable tablet or a flavored liquid suspension.

The inclusion of Pectin adds a demulcent quality. Pectin is a structural polymer that is capable of providing a protective film over irritated mucous membranes. This demulcent property helps to soothe and protect the lining of the intestines, differentiating the combination from simple mineral adsorbents.

Diagit's Non-Systemic Action and General Benefit

The mechanism principle of Diagit involves the dual physical processes of adsorption and mucosal protection. The high surface area of Attapulgite facilitates adsorption, physically binding to irritants and excess water in the gut, while Pectin contributes the protective coating.

This localized, non-systemic action provides the general benefit of stabilizing stool consistency and reducing fluid loss. By containing these disruptive agents and excess water, Diagit aids in restoring a more balanced environment within the gastrointestinal tract, thereby alleviating the primary symptoms of intestinal discomfort.

What side effects are possible with Diagit?

Possible Side Effects and Safety Information

The information below summarizes the officially documented safety profile of Diagit, based on regulatory evaluations and product labeling. It details adverse reactions and safety restrictions without providing medical advice or instructions for use.

Adverse Reactions Classified by Frequency

Adverse reactions are classified according to their frequency observed in clinical studies:

  • Very Common (Affecting 10% or more of patients): Somnolence (drowsiness), decreased appetite, and decreased weight.
  • Common (Affecting 1% to less than 10% of patients): Thrombocytopenia (low platelet count), neutropenia (low white blood cell count), fatigue, and elevated levels of liver enzymes (ALT and AST).

Serious and Clinically Significant Risks

Specific serious risks documented in regulatory materials involve key body systems:

  • Hematologic Risks: Diagit use has been associated with clinically significant decreases in blood cell counts, specifically neutropenia and thrombocytopenia. Monitoring of blood counts is a required safety measure.
  • Psychiatric Risks: Serious adverse reactions include reports of suicidal behavior and ideation.

Safety Restrictions and Limitations

The regulatory documentation specifies limitations on the use of Diagit:

  • Organ Function Restrictions: Diagit administration is not recommended for patients who have moderate or severe renal impairment or moderate or severe hepatic impairment.
  • Pediatric Population: The safety and effectiveness of Diagit have not been established in pediatric patients less than 6 months of age or weighing less than 7 kg.

Safety Monitoring

Official safety programs (such as the Risk Evaluation and Mitigation Strategy) require ongoing monitoring for key risks, including somnolence, significant decreased weight or appetite, neutropenia, thrombocytopenia, and changes in mental state or behavior.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdoses involving Diagit can be fatal and are primarily characterized by severe effects on the cardiovascular and central nervous systems, according to official regulatory information. Taking higher than recommended doses can lead to serious cardiac events, including QT interval and QRS complex prolongation, life-threatening ventricular arrhythmias such as Torsades de Pointes, and cardiac arrest.

Documented Overdose Symptoms

The clinical signs of overdose documented in official labeling extend beyond the heart and include serious Central Nervous System (CNS) depression. Symptoms can present as stupor, confusion, and loss of consciousness, along with the narrowing of the pupils. Gastrointestinal complications such as severe constipation and nausea have also been reported.

When to Seek Immediate Medical Help

Immediate medical attention or calling emergency services is required following a suspected overdose or if any associated symptoms occur. These urgent symptoms include fainting, unresponsiveness, or a rapid/irregular heartbeat. Due to the possibility of delayed CNS effects, a patient who has experienced an overdose must be monitored closely for a minimum of 48 hours in a medical setting.

Therapeutic Uses of Diagit

The therapeutic focus of Diagit is the symptomatic management of acute digestive upset. This medication is used to provide relief for conditions presenting with acute episodes of gastrointestinal distress.


Relief from Acute Diarrhea and Unstable Stool Characteristics

Diagit is commonly used to help with conditions characterized by episodic or fluctuating manifestations of diarrhea, helping to address symptom clusters that may become intense or disruptive. It is relevant for managing symptoms such as loose or watery stools, increased frequency of defecation, and gastrointestinal discomfort. The medication is relevant when supportive symptom management is appropriate and may assist with reducing the overall symptom load.


Easing Gastrointestinal Discomfort and Irritation

This combination is applied in scenarios where additional management of discomfort is required, particularly symptoms related to inflammatory or irritative states in the gut. The medication contributes to improved comfort during periods of heightened symptoms by helping to ease general gastrointestinal discomfort and associated cramping. This supportive action helps maintain a sense of stability when symptoms are more noticeable and supports general well-being during symptomatic phases.


Quick Fact: Relief for Acute Symptoms Diagit is relevant for easing symptoms associated with acute episodes, including altered stool characteristics and gastrointestinal discomfort.

Eligibility and Restrictions for Use

Who Can and Cannot Use Diagit? (Population Eligibility)

The use of Diagit (Attapulgite and Pectin) is strictly defined by official regulatory labeling, focusing on specific age groups, pre-existing conditions, and the underlying cause of diarrhea. The non-systemic nature of this intestinal adsorbent primarily guides its restrictions.


Contraindicated Populations

Diagit is absolutely contraindicated for patients with known or suspected intestinal obstruction or severe constipation, as its adsorbent action may worsen these conditions. It must also not be used by individuals with a known hypersensitivity to any of its components. Regulatory guidelines restrict use for diarrhea associated with high fever, blood in the stool, or confirmed cases of infectious colitis (such as Pseudomembranous Enterocolitis).


Age and Physiological Restrictions

Population Group Regulatory Status
Children under 6 years Not recommended or avoid use
Adults and Adolescents Approved for acute, non-specific diarrhea
Older Adults (Geriatric) Use with caution due to increased risk of impaction
Pregnancy Use only when benefit outweighs risk
Lactation (Breastfeeding) Generally accepted as safe

Eligibility is defined by official documents, which advise caution for use in elderly or debilitated individuals and those with pre-existing kidney conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Diagit (Attapulgite/Pectin) is structured around its non-systemic, intestinal adsorbent action, which leads to a pharmacokinetic absorption interference with co-administered oral agents. This effect necessitates specific administration constraints documented in regulatory guidance.

Interaction Scope

Category Official Regulatory Information
Medicinal product categories with documented interactions: Oral Medications Requiring Systemic Absorption (e.g., Antibiotics, Cardiac Glycosides), Opiate Analgesics, Vitamins and Minerals.
Specific interacting medicines (if explicitly listed): Quinolone Antibiotics (e.g., ciprofloxacin), Tetracycline Antibiotics, Digoxin.
Mechanistic basis of interactions (only if stated in label): Pharmacokinetic Interaction (PK) via physical adsorption in the gastrointestinal tract. Pharmacodynamic Interaction (PD) resulting in an additive constipating effect.
Timing-based interaction rules: Co-administered oral medications must be administered at least 2 hours before or 4 to 6 hours after Diagit to minimize binding interference.
Population-specific interaction notes: Caution is documented regarding the heightened potential for severe constipation or intestinal obstruction in elderly and debilitated individuals.
Interaction-related restrictions: No co-administration restrictions based on hepatic enzyme or transporter interactions are documented.

Interaction Classifications (High-Level)

The primary classification is a Clinically Significant Interaction due to the potential for reduced bioavailability of essential co-administered drugs. This profile is governed by principles outlined in authoritative regulatory data for adsorbent drug classes and results in a staggered dosing interval constraint for all oral agents.

Mechanism of Action

The action of Diagit is entirely non-systemic, relying on two physical mechanisms that alter fluid partitioning and physically shield the mucosal surface within the gastrointestinal lumen.

Physical Adsorption for Luminal Stabilization

This domain focuses on the primary function of Attapulgite, a highly porous clay mineral. Its large surface area facilitates adsorption, the physical binding of excess water and dissolved solutes onto its surface. This mechanistic cascade directly alters the solids-to-water partitioning within the intestinal contents, resulting in the physiological consequence of a higher consistency of the luminal mass.

Demulcent Action for Mucosal Protection

This domain describes the action of Pectin, a plant-derived polysaccharide, which forms a viscous, colloidal gel when hydrated. This property enables the creation of a viscous physical barrier (demulcent action) that adheres to the surface of the intestinal mucosa. This physical barrier limits the direct contact of irritants with the underlying epithelial tissue and sensory pathways, which results in the dampening of local sensory pathway activation.

Non-Systemic Mechanistic Synergy

The two mechanisms operate synergistically: adsorption reduces the volume of free water and solutes, while demulcent action physically protects the irritated mucosal surface. Because neither ingredient is significantly absorbed, this dual modality focuses its action strictly on the local environment, influencing the physical composition of the luminal contents and providing a barrier function for the mucosa without engaging systemic regulatory pathways.

Dosage and Administration Information

How to Use Diagit

Diagit, a combination drug containing Attapulgite and Pectin, is administered exclusively via the oral route for short-term symptomatic use. The product is typically available in two main forms: a solid tablet and a flavored liquid suspension. Official administration protocols establish precise dosing based on the occurrence of the symptom, rather than a fixed time schedule.

The frequency of use is event-driven, meaning a dose is taken after each loose bowel movement. For adults and adolescents, the standard dose is two units (tablets or equivalent measure of suspension) per event. This must not exceed a maximum limit of 12 units within any 24-hour period.

Population-Specific and Contextual Use

Usage instructions differentiate dosing for younger patients. Children aged 6 to 12 years are to be given a single one-unit dose after each event, with a 24-hour maximum of 6 units. The label specifies that administration to children under 6 years of age is restricted and requires consultation.

Regardless of the dosage form, the official protocol mandates taking Diagit with copious amounts of noncaffeine liquids. For the liquid form, the container must be shaken well before measuring the dose. Furthermore, due to the physical nature of the drug, it is a procedural requirement that Diagit be administered at least 2 hours before or 3 hours after any other oral medications to prevent interference with their absorption. The entire course of treatment is strictly limited to a maximum duration of 48 hours, characterizing it as a short-term therapeutic option.

Recent Clinical Evidence

Research evidence / Overview of studies for Diagit

Evidence for Use in Acute, Non-Specific Diarrhea

The core of the research for the components in Diagit was studied for conditions associated with acute or disruptive episodes, specifically sudden-onset diarrhea that is not linked to a defined cause. The primary research foundation comes from short-term Randomized Controlled Trials (RCTs). Findings from these original trials are often consolidated through Systematic Reviews and Meta-analyses to examine the overall consistency of findings.

Research examined outcomes related to physical discomfort and the functional characteristics of the gut. Studies were monitored for changes in stool characteristics, specifically the frequency of bowel movements and improvements in stool consistency. Studies report how symptoms evolved in the observed populations during periods of increased symptom activity, describing patterns observed in the studies related to differences in the measured time to unformed stool compared to control groups. Research provides context but not individual predictions.


Evidence for Symptomatic Gastrointestinal Discomfort

The combination was also evaluated in studies examining patient-reported experiences related to associated symptoms. Studies monitored patient-reported outcomes describing perceived discomfort, focusing on symptoms like abdominal cramping and general gastrointestinal irritation. These reports were often collected as secondary data alongside the primary measures of stool stabilization. Findings describe group patterns, indicating that participants reported measurements of improved subjective comfort scores during the short-term course of the study.


Long-Term Studies and Follow-up Duration

The clinical trials for Diagit's components were designed to address acute symptoms, meaning the majority of the evidence collected is strictly short-term. Follow-up durations were limited, lasting only until the symptoms resolved, typically within a few days.

Consequently, long-term effects are not fully established. Research exploring durability of response, potential for chronic use, or extended outcomes related to the combination is lacking. The available data reflect only the immediate response to temporary physiological imbalance; research into continuous or long-duration use is not available.

Frequently Asked Questions (FAQ)

Common questions about Diagit (FAQ)


Q: How quickly can someone expect Diagit to start working?

Regulatory documents describe Diagit as a non-systemic agent intended for short-term symptomatic relief. Because the drug acts locally within the digestive tract, its effects, such as the stabilizing of stool consistency, are often described as being noticeable within a few hours of administration.


Q: Is Diagit considered a long-term treatment option?

No, Diagit is not intended for long-term use. Official protocols strictly limit the entire course of treatment to a maximum duration of 48 hours (two days). Using the product for longer than this limit may increase the potential risk of developing severe constipation or intestinal blockage due to its physical binding action.


Q: What are the most commonly reported side effects of Diagit?

Official summaries indicate that the most frequently reported side effects are related to the drug’s physical action in the digestive system. These generally include constipation, flatulence (gas), and mild abdominal discomfort. A complete description of potential adverse reactions is documented in the full safety information section.


Q: What kind of research has been done on Diagit?

The core research for Diagit has focused on the management of acute, sudden-onset symptoms. This evidence is primarily based on short-term Randomized Controlled Trials (RCTs). Studies have been monitored for outcomes like the time it took for the stool consistency to stabilize and improvements in patient-reported discomfort.


Q: Does Diagit interact with alcohol?

While no specific clinical interaction with alcohol is consistently documented in official labels, the general official guidance for antidiarrheal products suggests that the consumption of alcohol should be avoided during the treatment period for digestive upset.


Q: Does Diagit affect blood pressure?

Diagit is classified as a non-systemic intestinal adsorbent, meaning its active ingredients are not significantly absorbed into the bloodstream. Systemic effects on the cardiovascular system, such as changes to blood pressure, are not listed in the documented serious or common adverse reactions.


Q: Can Diagit be split, crushed, or chewed?

Diagit is available in both a tablet and a liquid suspension form. For the liquid, official administration instructions require shaking the container well before use. Regulatory guidance provides specific instructions for the liquid form, but explicit directions for splitting or crushing the solid tablet are not generally provided in the product labeling.


Q: How long does Diagit stay in the body after the last dose?

Because the medicine is not absorbed systemically, it stays localized in the gastrointestinal tract and is not found in the bloodstream. The drug components are physically excreted in the feces, meaning the physical action stops shortly after the substance has passed through the intestinal system.


Q: Does Diagit cause weight changes?

Official documentation indicates that decreased appetite and decreased weight are listed as 'Very Common' side effects. This data is based on safety monitoring reports for the drug’s components as described in official product labeling.


Q: Is it normal to feel tired after starting Diagit?

Yes, regulatory information lists Somnolence (drowsiness) and fatigue as possible adverse reactions. Somnolence is specifically classified as a 'Very Common' effect in the safety data. This classification indicates it is a frequently observed adverse reaction.


Q: What is the difference between Diagit and other drugs for the same condition?

Diagit is classified as an intestinal adsorbent that acts non-systemically by physically binding to excess water and irritants in the gut. This mechanism differs from other antidiarrheal medications that work by engaging body systems, such as slowing down intestinal movement (anti-motility agents).


Q: Can Diagit be taken with vitamins or supplements?

Official regulatory documents confirm that Vitamins and Minerals are included in the categories of products with documented interactions. Official labeling requires a staggered dosing interval when taking Diagit with other oral medications or supplements to prevent interference with their absorption. Details on this timing are available in the Interactions section.


Q: Is Diagit available as a generic medicine?

The primary active ingredient, Attapulgite, is an Over-the-Counter (OTC) monographed ingredient. This status means that medicines containing this ingredient are commonly available under multiple brand names and generic listings.


Q: Does Diagit have any known effect on mood or sleep?

Regulatory documents list Somnolence (drowsiness) as a common side effect, which can naturally affect the sleep/wake cycle. Furthermore, official safety summaries document serious adverse reactions related to suicidal behavior and ideation.


Q: Is there a risk of dependency or addiction with Diagit?

Diagit is not classified as a controlled substance by regulatory bodies. This classification indicates that the drug does not carry the official risk profile associated with dependency and addiction.


Q: What is the typical duration of treatment with Diagit?

Diagit is intended for short-term use only. While the maximum permitted duration is 48 hours, regulatory documents state the drug should be used only as needed until the symptoms resolve, which is often within 1 to 2 days.


Q: Why do some people stop taking Diagit?

The official guidance dictates stopping use when the symptoms have successfully resolved. Other reasons based on official warnings include the development of complications like severe constipation or if the diarrhea symptoms persist past the 48-hour maximum limit.


Q: What information is provided about Diagit in official patient leaflets?

Official patient leaflets and consumer information generally include key details on the drug's intended purpose, proper use and administration instructions, a summary of potential side effects, and necessary drug-to-drug interaction warnings.


Q: Are there any official warnings about driving or operating machinery while on Diagit?

Official product information warns that the drug can cause Somnolence (drowsiness). Due to this potential Central Nervous System (CNS) effect, official labeling contains a warning regarding the need for caution when performing tasks that require full mental alertness, such as driving or operating heavy machinery.


Q: What is the official advice on storing Diagit?

Official advice is to store the product at controlled room temperature, maintaining conditions below 30 C. To maintain quality and safety, the container must be kept tightly closed in its original package, and it must always be stored out of the sight and reach of children.


Q: What if Diagit doesn't seem to be working after a few weeks?

Regulatory guidance for this short-term medication specifies that if symptoms of diarrhea do not improve within 48 hours, the drug should be stopped. Official product information states that if symptoms continue or worsen, the drug should be stopped.


Q: Are there any common reasons why Diagit is stopped?

The most common official reason to stop the drug is that the treatment is complete once symptoms resolve. Other reasons include reaching the 48-hour maximum limit or developing complications such as severe constipation or intestinal obstruction.

How should Diagit be stored and disposed of?

The official storage and disposal requirements for Diagit are based on specific conditions documented by regulatory bodies to maintain the medicine's quality and safety.

Storage Conditions

Diagit must be stored at controlled room temperature, maintaining conditions below 30°C (86°F). The product must not be refrigerated or frozen. To ensure protection from moisture, the container must be kept tightly closed and stored in its original package. As a mandatory safety requirement, the medication must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired product should be returned to a drug take-back program or an authorized collection site. If no program is available, the medicine must be mixed with an unpalatable substance (such as dirt) and placed in a sealed container before disposal in household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diagit found in:

A-Z Index: